Clinical Trials
2 trialsNCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT01752426 2020-02-24
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
M.D. Anderson Cancer Center
Phase 1/2 Completed